Australia's most trusted
source of pharma news
Wednesday, 17 December 2025
Posted 16 December 2025 PM
Australian biotech Vaxxas has been granted a TGA licence to manufacture its high-density microarray patch (HD-MAP) at its biomedical facility in Brisbane.
The company recently installed robotic lines at the facility to enable aseptic manufacture of the patches, which have the potential to revolutionise vaccine delivery. The patches will be used in clinical trials as the company closes in on commercialisation.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.